Table 3.
Treatment | Target:Control Ratio | ||||||||
3 Hours | 6 Hours | 12 Hours | |||||||
MT1-MMP ± SEM | MMP-11 ± SEM | 18S rRNA ± SEM | MT1-MMP ± SEM | MMP-11 ± SEM | 18S rRNA ± SEM | MT1-MMP ± SEM | MMP-11 ± SEM | 18S rRNA ± SEM | |
Control | 1.00 ± 0.08 | 1.00 ± 0.10 | 1.00 ± 0.04 | 1.00 ± 0.08 | 1.00 ± 0.10 | 1.00 ± 0.04 | 1.00 ± 0.08 | 1.00 ± 0.08 | 1.00 ± 0.02 |
TGF-β | 0.49 ± 0.08 | 1.27 ± 0.06 | 1.27 ± 0.08 | 1.21 ± 0.09 | 0.82 ± 0.08 | 1.53 ± 0.10 | - | 0.74 ± 0.10 | 1.22 ± 0.04 |
IL-1β | 0.63 ± 0.06 | 0.96 ± 0.09 | 0.89 ± 0.04 | 1.25 ± 0.04 | 0.69 ± 0.02 | 1.09 ± 0.04 | 1.86 ± 0.02 | 0.87 ± 0.04 | 0.98 ± 0.02 |
IL-2 | 0.61 ± 0.14 | 0.96 ± 0.13 | 0.89 ± 0.05 | 0.63 ± 0.04 | 0.74 ± 0.02 | 1.16 ± 0.03 | 1.39 ± 0.04 | 0.72 ± 0.06 | 0.87 ± 0.02 |
IL-6 | 0.55 ± 0.02 | 0.88 ± 0.02 | 0.89 ± 0.04 | 0.90 ± 0.02 | 0.78 ± 0.04 | 1.03 ± 0.02 | 1.77 ± 0.04 | 0.66 ± 0.02 | 1.33 ± 0.04 |
IL-8 | 0.42 ± 0.02 | 1.04 ± 0.02 | 0.87 ± 0.02 | 0.87 ± 0.02 | 0.69 ± 0.02 | 1.06 ± 0.02 | 1.97 ± 0.04 | 0.70 ± 0.02 | 0.89 ± 0.02 |